Dermatologic
Also called PV, Caebra Selvatica, Pemphigus Vulgaris Acutus
Pemphigus Vulgaris is an autoimmune blistering disease characterized by production of IgG autoantibodies against desmogleins, adhesion molecules essential for cell-to-cell adhesion. Antibodies target primarily desmoglein 3 (mucosal involvement) and sometimes also desmoglein 1 (mucocutaneous disease).
Pemphigus Vulgaris typically manifests in adults aged 40-60 years, though it can develop at any age. It affects males and females roughly equally. The disease is more common in people of Mediterranean, Jewish (Ashkenazi Jewish particularly), and Indian ancestry. It is associated with certain HLA types. There is no strong genetic predisposition in most cases, and it is considered an acquired autoimmune disease.
Clinical trials for Pemphigus Vulgaris focus on corticosteroid-sparing immunosuppressive strategies, including azathioprine, mycophenolate mofetil, and rituximab (anti-B cell monoclonal antibody). Trials investigate rituximab monotherapy and combination approaches that may allow dose reduction or discontinuation of systemic corticosteroids. Newer biologic therapies targeting T cells and other immune pathways are under investigation. Management requires monitoring for corticosteroid toxicity and infections. Patients should consult with a dermatologist experienced in autoimmune blistering diseases.